Latest news and press releases about Dogwood Therapeutics, Inc. (DWTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia.
Price
| Price | $1.70 |
| Market Cap | $57M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.76 |
| EV / EBITDA | -2.30 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -47.85% |
| Return on Invested Capital | -35.62% |
| Return on Assets | -44.77% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BOLT · BRTX · CLRB · COCP · EDSA · ERNA · EVGN
Explore sector: Healthcare · Biotechnology
More sections of DWTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks